Business Model Breakdown
How Astrana Health Inc Makes Money
ASTH
Market Cap
$1.7B
Annual Revenue
$2.4B
Profit Margin
0.7%
Employees
1,900
The Short Version
Astrana Health operates as a physician-centric, technology-enabled healthcare company, primarily focused on value-based care models for Medicare Advantage and Medicaid beneficiaries. It partners with healthcare providers to manage patient populations, aiming to improve health outcomes while reducing costs. Revenue is generated largely through capitation payments (fixed monthly fees per patient) and risk pool settlements, where the company shares in savings achieved from efficient care delivery, alongside smaller streams from management fees and fee-for-service arrangements. By leveraging technology and physician networks, Astrana positions itself to capture a significant share of the shift from traditional fee-for-service to value-based care.
Where the Revenue Comes From
Capitation (~58% of FY25 Care Partners Revenue)
Risk pool settlements & incentives (~3% of FY25 Care Partners Revenue)
Management fee income & Fee-for-service & Other income (~3% of FY25 Care Partners Revenue)
Who buys: Medicare Advantage and Medicaid beneficiaries (patients), and healthcare providers (physicians, clinics, health systems).
Why It Works (Competitive Advantages)
- ✔Physician-centric, technology-enabled integrated care model
- ✔Focus on rapidly expanding Medicare Advantage and Medicaid value-based care segments
- ✔Outperforming sector average in recent performance (+31.7% vs +6.5% for healthcare tech)
Economic Moat: Narrow (Switching Costs (integrated physician networks and patient relationships), Intangible Assets/IP (proprietary technology and 'AI drug development' focus), Efficient Scale (as it gains more lives under management))
What Our Analysis Says
DVR Score as of May 7, 2026
Astrana Health maintains its high-risk, high-reward profile, leveraging a rapidly expanding value-based care market with a clear strategic vision, particularly in Medicare Advantage and Medicaid. The company exhibits robust revenue growth (56% YoY in FY2025, 52.6% expected Q1 2026) and outperformance against its sector. Analyst consensus remains a 'Strong Buy' with significant upside. However, a material concern arises from the declining net income in FY2025 despite strong revenue growth, indicating significant margin compression. While the balance sheet was strengthened post-bankruptcy, detailed current metrics are pending. The potential for 10x growth hinges on the company's ability to translate its impressive top-line expansion into sustainable and growing profitability, as projected by future EPS estimates, and to effectively integrate its 'AI-powered' initiatives to drive efficiency and competitive advantage.